Clinical Outcomes Following Definitive Concurrent Chemoradiotherapy in Patients With International Federation of Gynecology and Obstetrics (FIGO) Stage IB-IVA Carcinoma of the Cervix.

Background and aim Cervical malignancy among women is associated with substantial mortality and morbidity. This study aimed to determine the clinical outcomes of definitive concurrent chemoradiotherapy (CCRT) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA cervical carcinoma. Methods This was a prospective, single-arm, interventional (experimental) study. Patients with cervical carcinoma fulfilling the inclusion criteria were planned for CCRT with weekly cisplatin injections (40 mg/m²). Patients with biopsy-proven squamous cell or adenosquamous carcinoma of the cervix, aged 25-65 years, with node-negative (N0) or node-positive (N1) nonmetastatic (M0) disease were included. However, patients with multiple comorbidities, Eastern Cooperative Oncology Group performance status III/IV, previous treatment for cervical cancer, or a history of any other malignancy were excluded. Treatment planning for all patients was performed using a conventional 2D simulator, and patients were treated with 45 Gy external beam radiotherapy (RT) in 25 fractions. A parametrial boost was given after 45 Gy, up to 60 Gy, in patients with parametrial involvement. Data were analyzed using IBM SPSS Statistics for Windows, version 25.0 (released 2017; IBM Corp., Armonk, NY, USA), and the Fisher-Freeman-Halton exact test was applied to compare response rates among patients with different pretreatment FIGO stages. Fisher's exact test was used to compare response rates after treatment among different histological types. A p-value ≤0.05 was considered significant. Results Complete response was observed in 53 (42.7%) patients, while partial response was seen in 45 (36.2%) patients. Stable disease was present in 17 (13.8%) patients, while progressive disease was seen in nine (7.3%) patients. There was a significant difference in response rate across different pretreatment FIGO stages. In our clinical setting, routine human papillomavirus screening and vaccination are not uniformly implemented because of limited resources, inadequate organized screening programs, low public awareness, and financial constraints. This study evaluated the clinical outcomes of definitive CCRT in patients with cervical carcinoma in our population. Conclusions Radical CCRT with weekly cisplatin demonstrated favorable short-term treatment outcomes in patients with FIGO stage IB-IVA cervical carcinoma. Most patients achieved a favorable treatment response, supporting acceptable locoregional disease control.